



Personal information

First name(s) / Surname(s) **Milan Paul KUBELAC**

Address(es)

Telephone(s)

E-mail paulkubelac@gmail.com

Nationality

Date of birth

Work experience

2023 - present	Day Hospital Coordinator, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
2022 - present	Member of Ethical Committee, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
2022 - present	Subinvestigator, ARENSIA Exploratory Medicine Early Clinical Trials Unit, Cluj-Napoca, Romania
2021 - present	Health Care Provider Subrepresentative, Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania, ERN Euracan G2 Domain – Rare cancer of the female genital organs and placenta, European Commission
2020 - present	Specialist Physician, Medical Oncology, The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
2016 - 2019	Executive Board, Residents Group in Oncology and Radiotherapy, Romanian Society of Radiotherapy and Medical Oncology
2015 - 2019	Physician in training, Medical Oncology, (Residency Entry Exam: 922 / 950 pts.) The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania
2010 – 2013	Department Manager, Member of Directory Committee, Romanian Students` Surgery Society, Romania
2009 – 2010	Biochemistry research group member, Department of Medical Biochemistry, “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca, Romania

Education and training

January – March 2023	Harvard Medical School, HMX Pro Genetics – Cancer Genomics and Precision Oncology
October 2021 – January 2022	NEMHESYS course on Next Generation Sequencing “NGS Master Class”, University of Salamanca, Spain
February – December 2020	Journal of Clinical Oncology’s Reviewer Mentoring Program, American Society of Clinical Oncology
October 2020	Project Management Course, Ministry of Labour and Social Protection, Romania
January – October 2020	Academy of Researchers Entrepreneurs in Medicine, POCU/380/6/13/125171
June – July 2017	European Society for Medical Oncology European Integration Fellowship Institute Gustave Roussy, Paris, France, Department of Gynaecological Cancers
2016 – 2022	PhD in Medicine, Evolutionary perspectives in ovarian cancer, “Summa cum laude” “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca

2008-2014	Doctor, General Medicine in accordance with E.U. curricula (<i>First at admission</i>) “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania				
2004 – 2008	Diploma of High School Graduation (<i>First of my Year</i>) Basic Topics, Intensive Mathematics, Informatics, English National College “Arany Janos” Salonta, Bihor Romanian Ministry of Education				
Personal skills and competences	<ul style="list-style-type: none"> • An excellent understanding of physical processes – 5 years (2003-2007) consecutive attendance as a county representative at the National Physics Olympics • Cambridge ESOL Certificate in Advanced English, Council of Europe Level C1, Grade B, December 2010 • Certificate of computer operating skills and computer medium programming skills, Ministry of Education Romania, September 2008 • Driving Licence, Category B, September 2008 				
Mother tongue(s)	Romanian				
Other language(s)					
Self-assessment	Understanding		Speaking		Writing
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	C1	C1	C1
French	A1	A1	A1	A1	A1
Social & organisational skills	Conceptualization, collaboration, communication, teamwork, delegation, planning, prioritizing Leadership – Students Representative of the University of Medicine and Pharmacy (2008-2010)				
Computer skills and competences	Good understanding in hardware and software principles, experience in working with Microsoft Windows, Microsoft Office, other related Windows programs, Multimedia applications, SPSS statistics				
Hobbies & leisure	Photography, Books, Skiing				
Additional information	Publications and scientific activity - available at the end of the document References available upon request				

PUBLICATIONS & SCIENTIFIC ACTIVITY

Books

1. Alexandra-Cristina Bot, Dana-Ioana Iancu, Milan-Paul Kubelac, Nicolae Todor, Patriciu Achimas-Cadariu, Tudor-Eliade Ciuleanu (Ed.). *Compendiu de Oncologie Medicală: principii și practică*. Cluj: Casa Cărții de Știință, 2021.
2. Achimas Cadariu P, Kubelac P, Irimie Alexandru. *Mezoteliomul peritoneal malign*. In Grigorescu M, Irimie A, Beuran M (Ed.), *Tratat de oncologie digestivă*, vol. III. București: Editura Academiei Române, 2015.
3. Lisecu C, Achimas Cadariu P, Kubelac P, Irimie A. *Cancerul rectului - Tratamentul chirurgical in boala locala si locoregionala*. In Grigorescu M, Irimie A, Beuran M (Ed.), *Tratat de oncologie digestivă*, vol. III. București: Editura Academiei Române, 2015.
4. Achimas Cadariu P, Lisencu C, Petrut B (Ed.), *Compendiu de Oncoginecologie in scheme si imagini*. Cluj: Editura Medicala Universitara "Iuliu Hatieganu" Cluj-Napoca, 2015.

Hirsch Index Web of Science: 10 (Jan 2024).

ISI Thomson Reuters papers

1. Yordanov A, Vasileva-Slaveva M, Galai N, Faraggi D, Kubelac MP, Tripac-Iacovleva I, et al. Cancer of the Cervix in Bulgaria: Epidemiology of a Crisis. *Healthcare*. 2023;11(3).
2. Roman A, Brozba A, Necula A, Muntean DD, Kubelac P, Fekete Z, et al. Usefulness of Saline Sealing in Preventing Pneumothorax after CT-Guided Biopsies of the Lung. *Diagnostics*. 2023;13(23).
3. Pasca A, Fischer-Fodor E, Jiboc NM, Kubelac PM, Saha B, Vlad C, et al. Meta-analyses reveal serum or plasma Interleukin-6 as a biomarker for malignant ovarian neoplasia. *Cytokine*. 2023;161.
4. Kubelac P. Treatment of ovarian sex cord stromal and germ cell tumours. *Int J Gynecol Cancer*. 2023;33(SUPPL 1):9-.
5. Kubelac P. Ovarian sex cord stromal and germ cell tumours. *Int J Gynecol Cancer*. 2023;33:8-.
6. Cheeseman S, Levick B, Sopwith W, Fenton H, Nam EJ, Kim D, et al. Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. *Frontiers in Oncology*. 2023;13.
7. Tripac I, Agius JC, Harasani K, Kubelac P, Stratan V, Tutuianu V, et al. Status of the Sentinel Lymph Node in Patients with Endometrial Cancer Stage I-II. *Chirurgia (Bucur)*. 2022;117(6):689-97.
8. Preda A, Ciuleanu T, Kubelac P, Todor N, Balacescu O, Achimas-Cadariu P, et al. Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricuta Oncology Institute series. *Esmo Open*. 2022;7(2).
9. Leskovská J, Miklášová N, Kubelac PM, Achimas-Cadariu P, Valentová J, Markuliak M, et al. Antiproliferative Ruthenium Complexes Containing Curcuminoid Ligands Tested In Vitro on Human Ovarian Tumor Cell Line A2780, towards Their Capability to Modulate the NF-κB Transcription Factor, FGF-2 Growth Factor, and MMP-9 Pathway. *Molecules*. 2022;27(14).
10. Kubelac P. Treatment of ovarian sex cord stromal and germ cell tumours. *Int J Gynecol Cancer*. 2022;32:10-.
11. Achimas-Cadariu P, Kubelac P, Irimie A, Berindan-Neagoe I, Rühli F. Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present. *J Ovarian Res*. 2022;15(1).
12. Yordanov A, Kostov S, Slavchev S, Strashilov S, Konsoulova A, Calleja-Agius J, et al. Adenosquamous Carcinoma of the Uterine Cervix - Impact of Histology on Clinical Management. *Cancer Management and Research*. 2021;13:4979-86.
13. Woopen H, Keller M, Braicu I, Zocholl D, Baum J, Krabisch P, et al. Health concerns in long-term survivors with ovarian cancer: Results of Expression VI-Carolin meets HANNA-Holistic Analysis of Long-term survival with Ovarian Cancer-The international NOGGO, ENGOT and GCIG survey. *J Clin Oncol*. 2021;39(15).
14. Vlad HS, Florea M, Nucu AM, Vlad IC, Cojocaru I, Vlad M, et al. 3D laparoscopic salvage radical prostatectomy: mini-series report and review of the literature. *Journal of Buon*. 2021;26(3):964-9.
15. Levick B, Cheeseman S, Nam EJ, Doh H, Lim S, Kim D, et al. OEN: Multi-center, international, real-world evidence studies performed using health records without data pooling-The use of a common data model and shared analytical methods. *J Clin Oncol*. 2021;39(15).
16. Kubelac P, Braicu C, Raduly L, Chiroi P, Nutu A, Cojocneanu R, et al. Comprehensive Analysis of the Expression of Key Genes Related to Hippo Signaling and Their Prognosis Impact in Ovarian Cancer. *Diagnostics*. 2021;11(2).
17. Kubelac MP, Vlad C, Pop B, Fetica B, Fischer-Fodor E, Soritau O, et al. Perioperative dynamic evaluation of folate receptor alpha expression in ovarian carcinoma. *Int J Gynecol Cancer*. 2021;31:A207-A8.
18. Hall G, Cheeseman S, Levick B, Nam EJ, Lim S, Classe JM, et al. An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes. *J Clin Oncol*. 2021;39(15).
19. Gaia-Oltean AI, Pop LA, Cojocneanu RM, Buse M, Zimta AA, Kubelac P, et al. The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma. *American Journal of Cancer Research*. 2021;11(4):1754-69.
20. Di Fiore R, Suleiman S, Ellul B, O'Toole SA, Savona-Ventura C, Felix A, et al. GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors-Current Challenges and Future Directions. *Cancers*. 2021;13(3).
21. Bonci EA, Titu S, Petrusan AM, Hossu C, Gata VA, Ghomi MT, et al. Does Surgical Margin Width Remain a Challenge for Triple-Negative Breast Cancer? A Retrospective Analysis. *Medicina-Lithuania*. 2021;57(3).
22. Rusu CB, Bujoreanu CE, Irimie A, Achimas-Cadariu P, Vlad C, Kubelac P, et al. Totally intracorporeal 3D laparoscopic orthotopic neobladder reconstruction following radical cystectomy for infiltrative bladder tumors: the

- experience of modified Studer and modified Y-shaped ileal reconstruction techniques. *Journal of Buon*. 2020;25(1):286-94.
23. Kubelac P, Genestie C, Auguste A, Mesnage S, Le Formal A, Pautier P, et al. Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. *Cancers*. 2020;12(3).
 24. Kubelac P, Craciun A, Jalba O, Gheorghe S, Lazar G, Ignat F, et al. Institutional results of OncoOVARIAN Dx - a novel algorithm for the preoperative evaluation of adnexal masses. *Journal of Buon*. 2020;25(3):1658-63.
 25. Gata VA, Kubelac PM, Buiga R, Vlad IC, Valean D, Muntean MV, et al. The value of tumor infiltrating lymphocytes as prognostic factor for lymph node status and survival amongst patients with cutaneous malignant melanoma. *Journal of Buon*. 2020;25(6):2700-7.
 26. Cheeseman S, Levick B, Nam E, Lim S, Rouzier R, Bonneau C, et al. Real world retrospective study of patients with epithelial ovarian cancer: an international comparison. *Int J Gynecol Cancer*. 2020;30:A75-A6.
 27. Moisoiu V, Stefanu A, Gulei D, Boitor R, Magdo L, Raduly L, et al. SERS-based differential diagnosis between multiple solid malignancies: breast, colorectal, lung, ovarian and oral cancer. *Int J Nanomedicine*. 2019;14:6165-78.
 28. Kubelac P, Vlad C, Berindan-Neagoe I, Irimie A, Achimas-Cadariu P. The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients. *Journal of Buon*. 2019;24(4):1538-43.
 29. Kubelac P, Craciun AM, Jalba O, Lazar G, Ignat FL, Lisencu IC, et al. Institutional results of oncoovarian dx: a novel algorithm for the management of adnexal masses. *Int J Gynecol Cancer*. 2019;29:A427-A.
 30. Vlad C, Dina C, Kubelac P, Vlad D, Pop B, Achimas-Cadariu P. Expression of toll-like receptors in ovarian cancer. *Journal of Buon*. 2018;23(6):1725-31.
 31. Kubelac P, Auguste A, Genestie C, Mesnage S, Le Formal A, Achimas-Cadariu P, et al. Changes in DNA damage response markers with treatment in advanced ovarian cancer. *Gynecol Oncol*. 2018;149:164-5.
 32. Vlad C, Kubelac P, Alexandru I, Achimas-Cadariu P. Preliminary study on the role of secondary surgery in ovarian cancer patients. Experience of a tertiary institution. *Journal of Buon*. 2017;22(3):802-3.
 33. Achimas-Cadariu P, Iancu M, Kubelac P, Pop F, Braicu I, Vlad C, et al. Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO-ENGOT trial: EXPRESSION III. *Eur J Cancer Care (Engl)*. 2017;26(6).
 34. Vlad C, Kubelac P, Onisim A, Fetica B, Fulop A, Irimie A, et al. Expression of CDCP1 and ADAM12 in the ovarian cancer microenvironment. *Journal of Buon*. 2016;21(4):973-8.
 35. Vlad C, Kubelac P, Alexandru I, Achimas-Cadariu P. The role of primary debulking in advanced ovarian cancer patients. *Journal of Buon*. 2016;21(5):1320-.
 36. Onisim A, Iancu M, Vlad C, Kubelac P, Fetica B, Fulop A, et al. Expression of Nestin and CD133 in serous ovarian carcinoma. *Journal of Buon*. 2016;21(5):1168-75.
 37. Vlad C, Kubelac P, Vlad D, Irimie A, Cadariu PA. Evaluation of clinical, morphopathological and therapeutic prognostic factors in rectal cancer. Experience of a tertiary oncology center. *Journal of Buon*. 2015;20(1):92-9.
 38. Vlad C, Kubelac P, Onisim A, Irimie A, Achimas-Cadariu P. The role of CDCP1 (CUB domain-containing protein 1) and ADAM12 (a disintegrin and metalloproteinase 12) in ovarian cancer. *Journal of Buon*. 2015;20(3):673-9.
 39. Vlad C, Kubelac P, Fetica B, Vlad D, Irimie A, Achimas-Cadariu P. The prognostic value of FOXP3(+) T regulatory cells in colorectal cancer. *Journal of Buon*. 2015;20(1):114-9.
 40. Onisim A, Achimas-Cadariu A, Vlad C, Kubelac P, Achimas-Cadariu P. Current insights into the association of Nestin with tumor angiogenesis. *Journal of Buon*. 2015;20(3):699-706.
 41. Kubelac MP, Fetica B, Vlad IC, Fulop A, Popa A, Achimas-Cadariu P. The Role of Inhibitor of DNA-binding 1 (ID-1) Protein and Angiogenesis in Serous Ovarian Cancer. *Anticancer Res*. 2014;34(1A):413-6.

Oral presentations

1. Kubelac P - Clinical implications of molecular testing in ovarian cancer. 34-lea Congres al Societății Române de Radioterapie și Oncologie Medicală/ Al 9-lea Congres al Federației Societăților Române de Cancer „From research to daily clinical practice – sharing experience”, 2-5 November 2023, Cluj-Napoca, Romania
2. Kubelac P - How to sequence systemic treatment of mutated BRAF metastatic melanoma? / Systemic treatment of metastatic non-melanoma skin cancer (SCC and basal cell). 23rd Brazilian Congress of Cancerology, 28-29th July 2023, Salvador/Bahia, Brazil, Virtual
3. Kubelac P - Promisiunea testărilor genetice în cancerule ovariene. Forumul National de Gineco-Oncologie, 16-17 June 2023, Bucuresti, Romania.
4. Kubelac P - Impactul testării HRD în tratamentul sistemic al cancerului ovarian. Forumul National de Gineco-Oncologie, 30.09-01.10.2022, Bucuresti, Romania.
5. Kubelac P. Progrese tehnologice în tratamentul sistemic al cancerului ovarian. Conferința Natională Tehnologie & IHealth în Medicina Secolului XXI. 6-9 July, Targu-Mures, Romania.
6. Vlad C, Kubelac P, Cebotari O, Morariu D, Gata V, Muntean MV, Irimie A, Achimaș-Cadariu P. Chirurgia cancerului ovarian în contextul terapiilor sistemice actuale. Congresul National de Chirurgie. 8-11 June 2022, Sinaia, Romania.
7. Kubelac P. Rare ovarian tumors. Rare cancers – a continuous challenge. National multidisciplinary conference. 11-12 June 2021, Online.
8. Achimaș-Cadariu P, Kubelac P, Muntean M, Gata V, Oradan AV, Morariu D, Vlad C, Irimie A. Targeted surgery after neoadjuvant treatment in advanced ovarian cancer. National Conference of Surgery, 9-12 June 2021, Online.
9. Kubelac P. Long term management of metastatic EGFRm lung adenocarcinoma with tyrosine kinase inhibitors. „Prof. Dr. Ion Chiricuță” Oncology Days, 20-22 June 2019, Cluj-Napoca, Romania.
10. Kubelac P. A role for checkpoint inhibitors in oncogenic addicted lung adenocarcinoma. „Prof. Dr. Ion Chiricuță” Oncology Days, 20-22 June 2019, Cluj-Napoca, Romania.

11. Kubelac P. The role of angiogenesis in ovarian cancer, Ion Chiricuta Institute of Oncology Days, 12-14 June 2014, Cluj-Napoca, Romania.
12. Kubelac P. Possible therapeutic decisions in ovarian cancer using recent tumor biomarkers, National Conference of Surgery, 30 May - 1 June 2013, Sinaia, Romania.
13. Kubelac P. The significance of the erythrocyte sedimentation rate in the follow up of patients with differentiated thyroid carcinoma, Medicalis, 12-14 May 2011, Cluj-Napoca, Romania.

Poster presentations

1. Pasca A, Paun DL, Kubelac PM, Gata VA, Jiboc NM, Vlad CI, et al. #1004 Impact of hormone replacement therapy on the overall survival and progression free survival of ovarian cancer patients: a systematic review and meta-analysis. *International Journal of Gynecologic Cancer*. 2023;33(Suppl 3):A362-A. ESGO 2023 Congress, Istanbul, Turkey
2. Kubelac P, Avram A, Turcas A, Roman A, Piciu A, Pasca A, et al. #746 Molecular analysis of BRCA and hrd status from small biopsies in high grade serous carcinoma. a real-world comparative analysis. *International Journal of Gynecologic Cancer*. 2023;33(Suppl 3):A306-A7. ESGO 2023 Congress, Istanbul, Turkey
3. Frenel J-S, Guerin-Charbonnel C, Xu-Vuillard A, Cheeseman S, Kubelac P, Zenatri M, et al. #201 Real world evidence (RWE) on the efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer. a multicentre, international study. *International Journal of Gynecologic Cancer*. 2023;33(Suppl 3):A257-A. ESGO 2023 Congress, Istanbul, Turkey
4. Irina T, Valentina S, Valeriu T, Victor S, Jean CA, Mariela V-S, et al. #103 Epigenetic silencing of MLH1 as a prognostic factor for endometrial cancer recurrence. *International Journal of Gynecologic Cancer*. 2023;33(Suppl 3):A131-A2. ESGO 2023 Congress, Istanbul, Turkey
5. Kubelac P, Catalin V, Pasca A, et al 2022-RA-1405-ESGO Indocyanine green in near-infrared light for intra-operative imaging of residual ovarian cancer after neoadjuvant chemotherapy. Initial experience. *International Journal of Gynecologic Cancer* 2022;32:A333. ESGO Congress 2022, Berlin, Germany
6. Pasca A, Fischer-Fodor E, Jiboc NM, Kubelac PM et al 2022-RA-437-ESGO Meta-analyses reveal serum or plasma interleukin-6 as a biomarker for malignant ovarian neoplasia *International Journal of Gynecologic Cancer* 2022;32:A233-A234. ESGO Congress 2022, Berlin, Germany
7. Kubelac MP, Vlad C, Pop B, Fetica B, Fischer-Fodor E, Soritau O, Balacescu O, Ignat F, Lazar G, Lisencu C, Rancea A, Irimie A, Achimas-Cadariu P. Perioperative dynamic evaluation of folate receptor alpha expression in ovarian carcinoma. *Int J Gynecol Cancer*. 2021;31:A207-A8 ESGO Congress 2021, Prague, Czech Republic
8. Kubelac P, Achimas-Cadariu P. Delayed interval debulking surgery in ovarian cancer. No evidence for acquired treatment resistance. *International Society for Evolution, Medicine, and Public Health 2021 Annual Meeting*, Lisboa, Portugal
9. Kubelac P, Vlad C, Pop B et al. Folate receptor alpha expression in serous ovarian carcinoma. 11th International Charité Mayo Conference: "Global Perspectives and Future Directions in Women's Cancer" 2021, Berlin, Germany
10. Wopen H, Keller M, Braicu I, Zocholl D, Baum J, Krabisch P, Boxler T, Wimberger P, Madronal C, Gil-Martin M, Bjelic-Radisic V, Trpchevski S, Samartzis EP, Heinzelmann-Schwarz VA, Achimas-Cadariu P, Kubelac P, Vardar MA, Jedryka MA, Vergote I, Schouli J. Health concerns in long-term survivors with ovarian cancer: Results of Expression VI-Carolin meets HANNA-Holistic Analysis of Long-term survival with Ovarian Cancer-The international NOGGO, ENGOT and GCIG survey. *J Clin Oncol*. 2021;39(15), ASCO 2021, Chicago, USA
11. Hall G, Cheeseman S, Levick B, Nam EJ, Lim S, Classe JM, Martin E, Kubelac P, Achimas-Cadariu P, Savva-Bordalo J, Borges M, Becker S, Shaid S, Niklas N, Guergova-Kuras M. An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes. *J Clin Oncol*. 2021;39(15), ASCO 2021, Chicago, USA
12. Levick B, Cheeseman S, Nam EJ, Doh H, Lim S, Kim D, Bocquet F, Martin E, Kubelac P, Achimas-Cadariu P, Calisto R, Magalhaes M, Becker S, Wolf A, Niklas N, Guergova-Kuras M, Hall G. OEN: Multi-center, international, real-world evidence studies performed using health records without data pooling-The use of a common data model and shared analytical methods. *J Clin Oncol*. 2021;39(15), ASCO 2021, Chicago, USA
13. Cheeseman S, Levick B, Nam E, Lim S, Rouzier R, Bonneau C, Kubelac MP, Achimas-Cadariu PA, Classe JM, Bocquet F, Becker S, Guergova-Kuras M, Hall G. Real world retrospective study of patients with epithelial ovarian cancer: an international comparison. *Int J Gynecol Cancer*. 2020;30:A75-A6, ESGO Congress 2020, Copenhagen, Denmark
14. Kubelac P, Craciun AM, Jalba O, Lazar G, Ignat FL, Lisencu IC, et al. Institutional results of oncoovarian dx: a novel algorithm for the management of adnexal masses. *International Journal of Gynecological Cancer*. 2019;29:A427-A, ESGO Congress 2019, Athens, Greece
15. Bonci E, Ghomi M, Hossu C, Țițu S, Petrușan A, Sandu A, Kubelac P et al. No ink on tumor" suffices for triple-negative breast cancers? ESSO Congress 2019, Rotterdam, Holland
16. Kubelac P, Vlad C, Berindan-Neagoe I, Irimie A, Achimas-Cadariu P. Ovarian cancer as a model for understanding tumor evolution in solid malignancies. *International Society for Evolution, Medicine, and Public Health 2019*, Zurich, Switzerland
17. Vlad C, Kubelac P, Pop B, Achimas-Cadariu P. The role of toll-like receptors in advanced stage ovarian cancer. *Charite-Mayo Conference 2019*, Berlin, Germany
18. Kubelac P, Vlad C, Berindan-Neagoe I, Irimie A, Achimas-Cadariu P. The clinical heterogeneity associated with BRCA mutations in advanced ovarian cancer. *Charite-Mayo Conference 2019*, Berlin, Germany
19. Kubelac P, Auguste A, Genestie C, Mesnage S, Le Formal A, Achimas-Cadariu P, Leary A. Changes in DNA damage response markers with treatment in advanced ovarian cancer. *Gynecologic Oncology*. 2018;149:164-5. 49th SGO Annual Meeting on Women's Cancer, 2018, New Orleans, USA.

20. Onisim A, Iancu M, Vlad C, Kubelac P, Achimaş-Cadariu P. Expression of CD146 in serous ovarian carcinoma. Charite-Mayo Conference 2017, Berlin, Germany
21. Vlad C, Kubelac P, Onisim A, Irimie A, Achimas Cadariu P. Expression of CDCP1 and ADAM12 in the ovarian cancer microenvironment. Charite-Mayo Conference 2015, Berlin, Germany
22. Onisim A, Achimas Cadariu A, Vlad C, Kubelac P, Achimas Cadariu P. Expression of nestin and CD133 in serous ovarian carcinoma. Charite-Mayo Conference 2015, Berlin, Germany
23. Kubelac MP, Fetica B, Vlad IC, Fulop A, Popa A, Achimas Cadariu P. The role of inhibitor of DNA-binding 1 (ID-1) protein and angiogenesis in serous ovarian cancer. Charite-Mayo Conference 2013, Berlin, Germany
24. Standardization of semiautomated method for serum PON1 activity, Medicalis, 13-15 May 2010, Cluj Napoca, Romania

Research Grants

	Title	Role	Timespan
1.	TRANSCAN-3 Next generation cancer immunotherapy: Targeting the tumour Microenvironment	Grant Member	2022-2025
2.	Modularea metalomica a transportorilor membranari in celulele tumorale ovariene chimiorezistente cu ajutorul nano-sensibilizatorilor PN-III-P4-PCE2021-1572	Grant Member	2022-2024
3.	European network for Gynaecological Rare Cancer research: From Concept to Cure COST Action CA18117	Management Committee Substitute	2019-2023
4.	Addressing the complex exposome profile in hormone-dependent cancers of the breast and prostate and its influence on tumoral genome PN-III-P4-ID-PCE-2016-0795	Grant Member	2019
5.	Complex frontier research project: New Targeted Optical Imaging NanoProbes for Near-Infrared (NIR) Real-Time (RT)Image-Guided Surgery of Ovarian Cancer. Babes Bolyai University and Prof. Dr. I.Chiricuta Oncology Institute Cluj-Napoca	Grant Member	2018-2022
6.	Intelligent system for evaluation of ovarian cancer risk PN-III-P2-2.1-CI-2018-1509. Prof. Dr. I. Chiricuta Oncology Institute Cluj-Napoca	Grant Member	2018
7.	PhD Research Grant 3066/29/01.02.2018 "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania	Grant Director	2016-2020
8.	Transfer de cunoştinţe în aplicaţii clinice ale biogenomicii în oncologie şi domenii conexe" BIOGENONCO, ID P_40_31 "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania	Grant Member	2017
9.	Students` Research Grant 22714/22/06.10.2011 "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania	Grant Director	2011-2012

National Conferences

1. Regional Institute of Oncology Conference, 23-25 November 2023, Iaşi, Romania
2. 34-lea Congres al Societăţii Române de Radioterapie şi Oncologie Medicală/ Al 9-lea Congres al Federaţiei Societăţilor Române de Cancer „From research to daily clinical practice – sharing experience”, 2-5 November 2023, Cluj-Napoca, Romania
3. Forumul National de Gineco-Oncologie, 16-17 June 2023, Bucuresti, Romania
4. Forumul National de Gineco-Oncologie, 30.09-01.10.2022, Bucuresti, Romania
5. Conferinta Nationala Tehnologia & IHealth in Medicina Secolului XXI. 6-9 July, Targu-Mures, Romania.
6. 32nd Annual Congress of the Romanian Society for Radiotherapy and Medical Oncology, 14-16 October 2021, Cluj, Romania
7. Rare cancers – a continuous challenge. National multidisciplinary conference. 11-13 June 2021
8. 29th Anual Congress of the Romanian Society for Radiotherapy and Medical Oncology, 17-19 October 2019, Cluj, Romania
9. Best of ASCO, 21-22 June 2019, Cluj-Napoca, Romania
10. The Oncology Institute “Prof. Dr. Ion Chiricuta” Cluj-Napoca Days, 20-22 June 2019, Cluj-Napoca, Romania
11. Best of ASTRO Romania – RSRMO, 17-18 May 2019, Cluj-Napoca, Romania
12. Insights in Hematology, 13-14 May 2019, Cluj-Napoca, Romania
13. Medicalis - International Congress for Medical Students and Young Health Professionals, 9-12 May 2019, Cluj-Napoca, Romania
14. 23rd Romanian German Course: Pediatric Neurosurgery, 11-13 April 2019, Cluj-Napoca, Romania
15. Challenges and perspectives in gynecology, 22-23 March 2019, Bucharest, Romania
16. Oncology in medical practice, 21-23 March, Bucharest, Romania
17. Immunotherapy in cancer, 22-24 February 2019, Timisoara, Romania
18. 5th National Congress of the Federation of Romanian Societies of Cancer, 4-7 October 2018, Sinaia, România
19. Young Oncology Cluj-Napoca, 5-7 July 2018, Cluj-Napoca, Romania
20. The 3rd National Congress of the Federation of Romanian Cancer Societies, 3-5 November 2016, Bucharest, Romania
21. University of Medicine and Pharmacy Days, 10-11 December, 2015, Tîrgu Mureş, Romania
22. Regional Institute of Oncology Conference, 27-29 November 2015, Iaşi, Romania

23. Anual Congress of the Romanian Society for Radiotherapy and Medical Oncology, 15-17 October 2015, Sibiu, Romania
24. Organisation of European Cancer Institutes Oncology Days 2014, Cluj-Napoca, Romania
25. Ion Chiricuta Institute of Oncology Days 2014, 12-14 June 2014, Cluj-Napoca, Romania
26. National Conference of Surgery, 30 mai - 1 iunie 2013, Sinaia, Romania
27. Medicalis, Cluj-Napoca 12-14 May 2011
28. Medicalis, Cluj-Napoca 13-15 May 2010
29. Medicalis, Cluj-Napoca 14-17 May 2009
30. National Conference of Neurooncology, 20-22 November 2008

International Conferences

1. ESGO 2023 Congress, 28 September – 1 October, Istanbul, Turkey
2. GYNO CARE COST Action (CA18117) Conference: 'Our battle for better healthcare is eternal', 2-3 July 2023, Sofia, Bulgaria
3. ASCO Annual Meeting, 2-6 June 2023, Chicago, USA
4. EURACAN Board Meeting 2023, 16-17 May 2023, Lyon, France
5. ESMO Breast Cancer Congress, 11-13 May 2023, Berlin, Germany
6. GYNO CARE COST Action (CA18117) Conference: 'Bridging the gap between Research and Cure in Rare Gynaecological Cancers: Where do we stand?', 17-18 February 2023, Napoli, Italy
7. ESMO 2022 Congress, 27-30 October, Berlin, Germany
8. European Lung Cancer Congress, 29 March-01 Apr 2023, Copenhagen, Denmark
9. ESGO 2022 Congress, 27-30 October, Berlin, Germany
10. Molecular Analysis for Precision Oncology Congress, 14-16 October 2022, Amsterdam, Netherlands
11. ESMO 2022 Congress, 9-13 September 2022, Paris France
12. ASCO Annual Meeting, 3-7 June, 2022, Virtual
13. ESMO Gynaecological Cancers Congress, 17-18 June 2022, Virtual
14. Charite Mayo Conference 2022 Distilled Update on Women's Cancer, 9 April 2022, Virtual
15. ESGO Annual Meeting, 23-25 October, 2021, Virtual
16. ESMO Virtual Congress 2021, 16-21 September 2021, Virtual
17. ASCO Annual Meeting, 4-8 June, 2021, Virtual
18. 11th International Charité Mayo Conference Global Perspectives and Future Directions in Women's Cancer, 5-8 May, 2021, Virtual
19. ASCO Annual Meeting, 29-31 May 2020, Virtual
20. ESMO Virtual Congress 2020, 19-21 September 2020, Virtual
21. ESMO Breast Cancer Virtual Meeting, 23-25 May 2020, Virtual
22. ASCO Annual Meeting, 31 May - 4 June 2019, Chicago, USA
23. Charite-Mayo Updates in Gynecology - Global Perspectives and Future Directions in Women's Cancer, 3-6 April 2019, Berlin, Germany
24. ESMO 2018 Congress, 19-23 October, Munchen, Germany
25. 49th SGO Annual Meeting on Women's Cancer, March 24-27, 2018, New Orleans, USA
26. Charite-Mayo Updates in Gynecology - A global perspective, 3-6 May 2017, Berlin, Germany
27. ESMO Symposium on Immuno-oncology 2015, 20-21 November 2015, Lausanne, Switzerland
28. Charite-Mayo Updates in Gynecology - A global perspective, 15-18 April 2015, Berlin, Germany
29. Charite-Mayo Conference: Updates in Gynecology - A global perspective, 17-20 April 2013, Berlin, Germany

National Courses

1. 27-29 June 2019: 14th Postuniversity course: Current tendencies and perspectives in oncology, Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania
2. 28-30 June 2018: 13th Postuniversity course: Current tendencies and perspectives in oncology, Ion Chiricuta Institute of Oncology, Cluj-Napoca, Romania
3. 9 December 2016: Legislative updates in medical practice – controversies: Cluj-Napoca, Romania
4. 5-6 November 2016: Updates in targeted molecular therapy, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
5. 26 November 2015: Therapeutic strategies in advanced ovarian cancer, Regional Institute of Oncology, Iași, Romania
6. 12-14 November 2015: Postuniversity course “PET/CT in Oncology”, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
7. 16-17 October 2015: Postuniversity course “Updates in targeted therapies”, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
8. 31 May – 2 June 2012: Certificate of attendance, the XVth National Conference of the Romanian Society of Ultrasonography in Medicine and Biology - Ultrasonography for medical students, Cluj-Napoca, Romania
9. Multimodal treatment in oncology sessions The Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-Napoca, Romania: 19 June 2015 – Quality of life in women with premalignant and malignant gynaecologic pathology at reproductive age / 23 November 2015 - Breast Cancer / 22 February 2016 - Prostate Cancer / 25 April 2016 - Hepatic & Pancreas Cancer / 27 June 2016 - Ovarian Cancer / 10 October 2016 - Cervical cancer / 14 November 2016 - Thyroid cancer / 21 November 2016 - Management of premalignant cervical lesions / 16 December 2016 - Adrenal cancer / 20 February 2017 - Breast cancer / 27 March 2017 - Colorectal cancer / 22 May 2017 - Endometrial Cancer / 12-13 June 2017 – Personalized medicine in the “omics” era / 3 July 2017 - Evolutionary medicine / 26 October 2017 - Gastric

Cancer / 26 April 2018 - Recent progress in oncology / 02 October 2019 – Thyroid Cancer / 07 November 2019 – Adrenal Tumors / 9 June 2022 – Ovarian Cancer / 16 June 2022 – Colorectal Cancers / 26 June 2022 – Melanoma / 5 December 2022 – Hepato-biliary cancers.

International Courses

1. 8-9 November 2023: Lung Clinical Observational Program, Padova University, Padova, Italy
2. GYNOCARE COST Action (CA18117) Training School: 'They are rare, but they are there', 29 June-1 July 2023, Sofia, Bulgaria
3. 5-6 May 2023: ESMO Advanced Course on Precision Oncology Across Tumours: Tumour-Agnostic and Tumour-Modulated, Lisbon, Portugal
4. 28-29 April 2023, 7th CECOG Pancreas Cancer Academy, Vienna, Austria
5. 28-29 November 2022: Clinical Observational Program cervical & endometrial cancer, Agostino Gemelli University Policlinic, Rome, Italy
6. 13-14 May 2022: ESMO Preceptorship on Colorectal Cancer, Valencia, Spain
7. 23-25 February 2021: Oncology acadeMe Virtual Masterclass on Safety Management of Immuno-Oncology Therapies, Germany
8. 29 November – 1 December 2019: 4th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, Milano, Italy
9. 10-13 June 2019: Summer School in Oncology - Rom Society of Radiotherapy, Trestioreanu Foundation, Federation of Romanian Cancer Societies, CECOG College, Medical University Vienna International, Bucharest, Romania – Invited speaker
10. 12-17 April 2019: 6th European School of Oncology - European Society for Medical Oncology Eastern Europe and Balkan Region Masterclass in Medical Oncology, Sibenik, Croatia
11. 28-30 March 2019: Eastern Europe and Balkan Region Refresher Course on Lung Cancer, Budapest, Hungary
12. 15 February 2019: European Cooperation in Science and Technology (COST) Academy Leadership Workshop, Brussels, Belgium
13. 11-15 June 2018: Summer School in Oncology - Rom Society of Radiotherapy, Trestioreanu Foundation, Federation of Romanian Cancer Societies, CECOG College, Medical University Vienna International, Bucharest, Romania – Invited speaker
14. 21-22 April 2017: European Society for Medical Oncology Preceptorship on Ovarian Cancer, Prague, Czech Republic
15. 16-17 September 2016: European Society for Medical Oncology Preceptorship on Breast Cancer, Lisbon, Portugal
16. 6-7 July 2016: European Society for Medical Oncology ESMO Preceptorship on Colorectal Cancer, Prague, Czech Republic
17. 13-17 June 2016: Summer School in Oncology - Rom Society of Radiotherapy, Trestioreanu Foundation, Federation of Romanian Cancer Societies, CECOG College, Medical University Vienna International, Bucharest, Romania
18. 20-25 May 2016: 3rd European School of Oncology - European Society for Medical Oncology Eastern Europe and Balkan Region Masterclass in Medical Oncology, Bratislava, Slovakia
19. 4-7 April 2016: European Society for Medical Oncology Translational Research Unit Visit 'How to develop a translational research project with clinical applicability, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale "F. Magrassi", Second University of Naples, Italy
20. 18-19 November 2015: European Society for Medical Oncology Preceptorship on Immunotherapy of Cancer, Zurich, Switzerland
21. 5-7 October 2015: Ovarian Cancer Academy, Charite Universitätsmedizin Berlin, ENGOT, ESGO, NOGGO, Institute of Oncology "Prof. Dr. Ion Chirircuta", Cluj-Napoca, Romania
22. 7-8 July 2015: European Society for Medical Oncology Preceptorship on NSCLC, Copenhagen, Denmark
23. 15-19 June 2015: Summer School in Oncology - Rom Society of Radiotherapy, Trestioreanu Foundation, Federation of Romanian Cancer Societies, CECOG College, Medical University Vienna International, Bucharest, Romania
24. 1-12 October 2012: Certificate of attendance, Dermato – Oncology, Prof. Giovanni Pellacani, Dept. of Dermatology, Policlinico Universitario Modena, Italy
25. 26 January – 3 February 2012: Theoretical aspects of robotic surgery in urology, The European Oncology Institute, Milano, Italy in collaboration with "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania
26. 8-19 August 2011: Certificate of attendance – Elective Course in Oncology for Medical Students, ECCO – the European CanCer Organisation; Poznan University of Medical Sciences, Poland
27. 2 – 28 August 2010: Clinical and laboratory diagnostics of rare and common genetic disorders, Department of Human and Medical Genetics, Vilnius University, Lithuania

Affiliations

1. American Society of Clinical Oncology Member, from 2019
2. European Society for Medical Oncology Member from 2015
3. European Society for Gynaecologic Oncology Member, from 2020
4. Romanian Society for Radiotherapy and Medical Oncology Member, from 2015
5. Societatea Națională de Oncologie Medicală din România Member, from 2023